BRPI1006547A2 - formas cristalinas, cloridato de saxagliptina, composição farmaceutic, processo para preparação da forma i-s de cloridato e saxagliotina, processo para preparação da forma ht de cloridato de saxagliptina uso de sexagliptina cristalino e uso da forma iv s de cloridato de saxagloptina - Google Patents

formas cristalinas, cloridato de saxagliptina, composição farmaceutic, processo para preparação da forma i-s de cloridato e saxagliotina, processo para preparação da forma ht de cloridato de saxagliptina uso de sexagliptina cristalino e uso da forma iv s de cloridato de saxagloptina

Info

Publication number
BRPI1006547A2
BRPI1006547A2 BRPI1006547A BRPI1006547A BRPI1006547A2 BR PI1006547 A2 BRPI1006547 A2 BR PI1006547A2 BR PI1006547 A BRPI1006547 A BR PI1006547A BR PI1006547 A BRPI1006547 A BR PI1006547A BR PI1006547 A2 BRPI1006547 A2 BR PI1006547A2
Authority
BR
Brazil
Prior art keywords
chloridate
saxagliptin
preparing
crystalline
sexagliptin
Prior art date
Application number
BRPI1006547A
Other languages
English (en)
Portuguese (pt)
Inventor
Arthur Pichler
Christoph Langes
Josef Wieser
Milica Vukicevic
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of BRPI1006547A2 publication Critical patent/BRPI1006547A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BRPI1006547A 2009-04-09 2010-04-09 formas cristalinas, cloridato de saxagliptina, composição farmaceutic, processo para preparação da forma i-s de cloridato e saxagliotina, processo para preparação da forma ht de cloridato de saxagliptina uso de sexagliptina cristalino e uso da forma iv s de cloridato de saxagloptina BRPI1006547A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16791809P 2009-04-09 2009-04-09
EP09157723 2009-04-09
EP09175259 2009-11-06
PCT/EP2010/054692 WO2010115974A1 (en) 2009-04-09 2010-04-09 Crystal forms of saxagliptin

Publications (1)

Publication Number Publication Date
BRPI1006547A2 true BRPI1006547A2 (pt) 2016-10-18

Family

ID=42935672

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006547A BRPI1006547A2 (pt) 2009-04-09 2010-04-09 formas cristalinas, cloridato de saxagliptina, composição farmaceutic, processo para preparação da forma i-s de cloridato e saxagliotina, processo para preparação da forma ht de cloridato de saxagliptina uso de sexagliptina cristalino e uso da forma iv s de cloridato de saxagloptina

Country Status (12)

Country Link
US (2) US20120088808A1 (enExample)
EP (1) EP2417107B1 (enExample)
JP (2) JP6088245B2 (enExample)
KR (1) KR20120006047A (enExample)
CN (2) CN102459170B (enExample)
AU (1) AU2010233718B2 (enExample)
BR (1) BRPI1006547A2 (enExample)
CA (1) CA2757934C (enExample)
ES (1) ES2548386T3 (enExample)
PL (1) PL2417107T3 (enExample)
RU (1) RU2539590C2 (enExample)
WO (1) WO2010115974A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0487425A (ja) * 1990-07-31 1992-03-19 Fujitsu Ltd 回線切り替え装置
CA2757934C (en) * 2009-04-09 2017-12-19 Sandoz Ag Crystal forms of saxagliptin
US20110313035A1 (en) * 2009-12-16 2011-12-22 Hetero Research Foundation Polymorphs of darunavir
US8853430B2 (en) 2010-05-20 2014-10-07 Hetero Research Foundation Crystalline hydrochloride salt of darunavir
US8410288B2 (en) 2010-10-04 2013-04-02 Teva Pharmaceutical Industries Ltd. Polymorphs of Saxagliptin hydrochloride and processes for preparing them
US20140302150A1 (en) 2011-09-07 2014-10-09 Umit Cifter Dpp-iv inhibitor formulations
EP2578208B1 (en) 2011-10-06 2014-05-21 Sanovel Ilac Sanayi ve Ticaret A.S. DPP-IV inhibitor solid dosage formulations
WO2013136343A1 (en) 2012-03-12 2013-09-19 Mylan Laboratories Ltd. Amorphous saxagliptin hydrochloride
US20150087686A1 (en) * 2012-04-25 2015-03-26 Enantia, S.L. Crystalline forms of saxagliptin
CA2885957C (en) 2012-05-24 2019-10-22 Apotex Pharmachem India Pvt. Ltd Salts of saxagliptin with organic acids
SG11201408619WA (en) 2012-07-02 2015-01-29 Ranbaxy Lab Ltd Saxagliptin salts
WO2015067223A1 (en) 2013-11-06 2015-05-14 Zentiva, K., S. L-tartrate salt of (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile and process for preparation thereof
JP2022182181A (ja) * 2021-05-27 2022-12-08 キョーリンリメディオ株式会社 ビルダグリプチン含有医薬品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032616B2 (ja) * 1976-08-24 1985-07-29 アレクサンダ− ガラツト 高い貯蔵安定性の無水アセチルサリチル酸ナトリウム
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7420079B2 (en) * 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
MX2007000625A (es) * 2004-07-16 2007-03-07 Warner Lambert Co Agentes activadores del crecimiento capilar.
US20060035954A1 (en) * 2004-08-11 2006-02-16 Sharma Padam N Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
PE20090696A1 (es) * 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
CA2757934C (en) * 2009-04-09 2017-12-19 Sandoz Ag Crystal forms of saxagliptin

Also Published As

Publication number Publication date
CN102459170B (zh) 2014-07-23
RU2011145054A (ru) 2013-05-20
EP2417107A1 (en) 2012-02-15
WO2010115974A1 (en) 2010-10-14
EP2417107B1 (en) 2015-08-26
JP2012523395A (ja) 2012-10-04
RU2539590C2 (ru) 2015-01-20
JP2016006063A (ja) 2016-01-14
CN104016902A (zh) 2014-09-03
US20120088808A1 (en) 2012-04-12
US9260389B2 (en) 2016-02-16
US20140200252A1 (en) 2014-07-17
ES2548386T3 (es) 2015-10-16
JP6088245B2 (ja) 2017-03-01
CA2757934C (en) 2017-12-19
AU2010233718B2 (en) 2015-11-05
CN104016902B (zh) 2017-10-20
AU2010233718A1 (en) 2011-10-27
PL2417107T3 (pl) 2016-02-29
CA2757934A1 (en) 2010-10-14
CN102459170A (zh) 2012-05-16
KR20120006047A (ko) 2012-01-17

Similar Documents

Publication Publication Date Title
BRPI1006547A2 (pt) formas cristalinas, cloridato de saxagliptina, composição farmaceutic, processo para preparação da forma i-s de cloridato e saxagliotina, processo para preparação da forma ht de cloridato de saxagliptina uso de sexagliptina cristalino e uso da forma iv s de cloridato de saxagloptina
BRPI0923923A2 (pt) composição condicionadora de tecidos, processo para preparação da composição, uso da composição,e , uso de um copolímero catiônico
BRPI0916609A2 (pt) Processo para a preparação de um macrociclo
BR112014000236A2 (pt) lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas
BR112014028755A2 (pt) composição de argamassa de poliuretano, processo para preparação da composição de argamassa de poliuretano, e, uso de uma composição de argamassa de poliuretano.
BRPI0924427A2 (pt) composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma
BR112013013127A2 (pt) processo para a preparação de derivados de morfolinil antraciclina
BR112013009486A2 (pt) processo para preparação de formas de dosagem gastrirretentivas multiparticuladas
BR112014028723A2 (pt) forma cristalina, seu processo de produção e mistura, agente de proteção, uso da forma cristalina e método para o combate
BRPI0918487A2 (pt) processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero
IL209805A0 (en) Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as phamaceuticals
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BR112012004321A2 (pt) pó de cristais de manitol definido, o respectivo processo da fabricação
BR112012010007A2 (pt) processo para fabricação de uma composição biodegradável, composição biodegradável, artigo biodegradável e uso da composição
BR112014009684A2 (pt) processo para preparar polímeros, polímero e uso de polímeros
BR112012008202A2 (pt) processo de preparação de uma composição, componentes e uso da composição
BR112012016201A2 (pt) ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
BRPI1007648A2 (pt) processo de preparação de uma espuma de poliamida, espuma, artigo e uso de uma composição
BR112014007568A2 (pt) composição farmacêutica, uso e processo para preparar a mesma
BRPI1014571A2 (pt) composições de combinação de lactona macrocíclica, vacinas e processos para produzir as mesmas
BR112012015039A2 (pt) composição, poliéster hiper-ramificado, processo para a preparação do ,poliéster hiper-ramificado e uso do poliéster hiper-ramificado
BR112012029225A2 (pt) processo para a preparação de um composto quiral, composto quiral e uso de um composto quiral
BRPI0912163A2 (pt) Composto químico, processo para a produção de um composto, compsição química, e, uso de um composto químico.
IL232058A (en) Processes for preparing 6 - chloro - 2, 3, 4, 9 - tetrahydro - 1h - carbazole - 1 - carboxamide and its starting materials
BRPI0915905A2 (pt) uso de derivados de pirimidilaminobenzamida para o tratamento de fibrose

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained
B350 Update of information on the portal [chapter 15.35 patent gazette]